A soybean plantation in Brazil. (MailsonPignata/iStock/Getty Images)

Brazilian court overturns ban on glyphosate

Brasilia | Reuters — A Brazilian court on Monday overturned an injunction banning products containing the herbicide glyphosate, knocking down a previous ruling that had been set to disrupt the soy planting season set to begin this month. A Brazilian judge ruled last month to halt the registration of new glyphosate-based products in the country […] Read more


(Bayer.com)

Roundup cancer verdict sends Bayer shares sliding

    Frankfurt | Reuters — Bayer shares plunged as much as 14 per cent on Monday, losing about US$14 billion in value, after newly acquired Monsanto was ordered to pay US$289 million in damages in the first of possibly thousands of U.S. lawsuits over alleged links between a weedkiller and cancer. After the verdict […] Read more







Bayer’s wheat breeding station at Pike Lake, Sask., southwest of Saskatoon. (Cropscience.bayer.com)

Canada clears Bayer’s Monsanto play, with conditions

Canada’s Competition Bureau says it’s “actively reviewing” BASF’s suitability as a buyer of the crop seed and chemical assets Bayer has to sell to get the bureau’s blessing to buy Monsanto. The Competition Bureau said Wednesday it has an agreement with Bayer to deal with “concerns that the proposed transaction would have significantly harmed competition […] Read more


(Pabradyphoto/iStock/Getty Images)

Bayer wins U.S. nod for Monsanto deal to create ag giant

Frankfurt/Washington | Reuters — Bayer won U.S. approval for its planned takeover of Monsanto after agreeing to sell about US$9 billion in assets, clearing a major hurdle for the US$62.5 billion deal that will create by far the largest seeds and pesticides maker. Makan Delrahim, who heads the U.S. Justice Department’s (DoJ) antitrust division, said […] Read more

(Bayer.com)

Bayer cuts Monsanto synergy target on divestments

Bonn | Reuters — Bayer said positive synergy effects from the planned takeover of U.S. seeds and chemical firm Monsanto would be about US$300 million below its previous target because it will sell more businesses than initially expected to get antitrust approval. Bayer CEO Werner Baumann again threw his weight behind the deal, despite higher […] Read more